摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-chloro-4-(3-chloro-4-methoxybenzylamino)-5-ethoxycarbonylpyrimidine | 330786-00-0

中文名称
——
中文别名
——
英文名称
2-chloro-4-(3-chloro-4-methoxybenzylamino)-5-ethoxycarbonylpyrimidine
英文别名
ethyl 2-chloro-4-[(3-chloro-4-methoxyphenyl)methylamino]pyrimidine-5-carboxylate
2-chloro-4-(3-chloro-4-methoxybenzylamino)-5-ethoxycarbonylpyrimidine化学式
CAS
330786-00-0
化学式
C15H15Cl2N3O3
mdl
——
分子量
356.208
InChiKey
SWSNZILYPHIOKE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.3
  • 重原子数:
    23
  • 可旋转键数:
    7
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.27
  • 拓扑面积:
    73.3
  • 氢给体数:
    1
  • 氢受体数:
    6

SDS

SDS:a66e086816d45a662467108dbadec32f
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    阿伐那非的合成方法
    摘要:
    本发明提供了一种阿伐那非的合成方法,化合物(18)与化合物(13)或(3)发生亲核取代反应,再经水解后得到化合物(21)或(22),再与烃基磺酰氯或特戊酰氯反应得到混合酸酐,混合酸酐与化合物(23)反应得到化合物(24)或(25),然后化合物(24)经氧化后与化合物(9)反应得到阿伐那非,或者化合物(25)直接与化合物(9)反应得到阿伐那非。本发明的合成方法可控性强、步骤简单,且收率高,成本低,适合于工业化生产反应路线如下:
    公开号:
    CN104710411B
  • 作为产物:
    参考文献:
    名称:
    Cyclic compounds
    摘要:
    化合物的公式(I)或其药理学上可接受的盐,其中X为═CH—或═N—,Y为—NH—,—NR4—,—S—,—O—,—CH═N—,—N═CH—,—N═N—,—CH═CH—等,R1为较低的烷氧基,氨基,含N原子的杂环环,或者由含N原子的杂环环取代的羟基(每个都可以取代),R2为较低的烷基氨基基,可以由芳基取代,较低的烷氧基,可以由芳基取代,由含N原子的芳基取代的较低的烷氧基,R3为芳基,含N原子的杂环环,较低的烷基,较低的烷氧基,环状较低的烷氧基,由含N原子的杂环环取代的羟基,或者氨基(每个都可以取代),R3和Y中的取代基可以结合形成内酯环。本发明的化合物具有优异的选择性PDE V抑制活性,因此,可用作治疗或预防因cGMP信号传导功能障碍引起的各种疾病的药物。
    公开号:
    US20040142930A1
点击查看最新优质反应信息

文献信息

  • Aromatic nitrogen-containing 6-membered cyclic compounds
    申请人:——
    公开号:US20030032647A1
    公开(公告)日:2003-02-13
    An aromatic nitrogen-containing 6-membered cyclic compound of the formula (I): 1 wherein Ring A is a substituted or unsubstituted nitrogen-containing heterocyclic group; R 1 is a substituted or unsubstituted lower alkyl group, —NH—Q—R 3 (R 3 is a substituted or unsubstituted nitrogen containing heterocyclic group, and Q is a lower alkylene group or a single bond), or —NH—R 4 (R 4 is a substituted or unsubstituted cycloalkyl group); R 2 is a substituted or unsubstituted aryl group; one of Y and Z is ═CH—, and the other is ═N—, or a pharmaceutically acceptable salt thereof, these compounds exhibiting excellent selective PDE V inhibitory activities, and hence, being useful in the prophylaxis or treatment of penile erectile dysfunction, etc.
    一种芳香性氮含量的6元环化合物,化学式为(I):其中环A是取代或未取代的含氮杂环基团;R1是取代或未取代的较低烷基基团,-NH-Q-R3(R3是取代或未取代的含氮杂环基团,Q是较低烷基烃基团或单键),或-NH-R4(R4是取代或未取代的环烷基基团);R2是取代或未取代的芳基团;Y和Z中的一个是═CH—,另一个是═N—,或其药学上可接受的盐,这些化合物表现出优异的选择性PDE V抑制活性,因此在预防或治疗阴茎勃起功能障碍等方面具有用处。
  • Aromatic nitrogen-containig 6-membered cyclic compounds
    申请人:Tanabe Seiyaku Co., Ltd.
    公开号:US20030229095A1
    公开(公告)日:2003-12-11
    An aromatic nitrogen-containing 6-membered cyclic compound of the formula (I): 1 wherein Ring A is a substituted or unsubstituted nitrogen-containing heterocyclic group; R 1 is a substituted or unsubstituted lower alkyl group, —NH—Q—R 3 (R 3 is a substituted or unsubstituted nitrogen containing heterocyclic group, and Q is a lower alkylene group or a single bond), or —NH—R 4 (R 4 is a substituted or unsubstituted cycloalkyl group); R 2 is a substituted or unsubstituted aryl group; one of Y and Z is ═CH—, and the other is ═N—, or a pharmaceutically acceptable salt thereof, these compounds exhibiting excellent selective PDE V inhibitory activities, and hence, being useful in the prophylaxis or treatment of penile erectile dysfunction, etc.
    一种含有芳香性质的氮,6元环化合物,化学式为(I):1,其中环A为取代或未取代的含氮杂环基团; R1为取代或未取代的低级烷基基团,-NH-Q-R3(R3为取代或未取代的含氮杂环基团,Q为低级亚烷基基团或单键),或-NH-R4(R4为取代或未取代的环烷基基团);R2为取代或未取代的芳基基团;Y和Z中的一个为═CH—,另一个为═N—或其药学上可接受的盐。这些化合物表现出优异的选择性PDE V抑制活性,因此在预防或治疗阴茎勃起功能障碍等方面具有用途。
  • Pyrazine derivatives
    申请人:Tanabe Seiyaku Co., Ltd.
    公开号:US07273868B2
    公开(公告)日:2007-09-25
    1. A cyclic compound of the formula (I) or a pharmacologically acceptable salt thereof, wherein X is ═CH— or ═N—, Y is —NH—, —NR4—, —S—, —O—, —CH═N—, —N═CH—, —N═N—, —CH═CH—, etc., R1 is a lower alkoxy group, an amino group, a heterocyclic ring containing N atom(s), or a hydroxy group substituted by a heterocyclic ring containing N atom(s) (each of which is optionally substituted), R2 is a lower alkylamino group which is optionally substituted by an aryl group, a lower alkoxy group which is optionally substituted by an aryl group, a lower alkoxy group substituted by an aromatic heterocyclic ring containing N atom(s), R3 is an aryl group, a heterocyclic ring containing N atom(s), a lower alkyl group, a lower alkoxy group, a cyclo lower alkoxy group, a hydroxy group substituted by a heterocyclic ring containing N atom(s), or an amino group (each of which is optionally substituted), and R3 and a substituent in Y may be combined to form a lactone ring. The compound of the present invention has excellent selective PDE V inhibitory activity and therefore, is useful as a therapeutic or prophylactic drug for treating various diseases due to functional disorders on cGMP-signaling.
    公式(I)的环状化合物或其药学上可接受的盐,其中X为═CH—或═N—,Y为—NH—、—NR4—、—S—、—O—、—CH═N—、—N═CH—、—N═N—、—CH═CH—等,R1为较低的烷氧基、氨基、含N原子的杂环环或由含N原子的杂环环取代的羟基(每个都可以选择性地取代),R2为较低的烷基氨基,可以选择性地被芳基取代,也可以选择性地被芳基取代的较低的烷氧基,被含N原子的芳香杂环环取代的较低的烷氧基,R3为芳基、含N原子的杂环环、较低的烷基、较低的烷氧基、环状较低的烷氧基、由含N原子的杂环环取代的羟基或氨基(每个都可以选择性地取代),R3和Y中的取代基可以结合形成内酯环。本发明的化合物具有出色的选择性PDE V抑制活性,因此,可用作治疗或预防因cGMP信号传导功能障碍引起的各种疾病的药物。
  • Pyrimidine compounds
    申请人:Tanabe Seiyaku Co., Ltd.
    公开号:US07220736B2
    公开(公告)日:2007-05-22
    A cyclic compound of the formula (I) or a pharmacologically acceptable salt thereof, wherein X is ═CH— or ═N—, Y is —NH—, —NR4—, —S—, —O—, —CH═N—, —N═CH—, —N═N—, —CH═CH—, etc., R1 is a lower alkoxy group, an amino group, a heterocyclic ring containing N atom(s), or a hydroxy group substituted by a heterocyclic ring containing N atom(s) (each of which is optionally substituted), R2 is a lower alkylamino group which is optionally substituted by an aryl group, a lower alkoxy group which is optionally substituted by an aryl group, a lower alkoxy group substituted by an aromatic heterocyclic ring containing N atom(s), R3 is an aryl group, a heterocyclic ring containing N atom(s), a lower alkyl group, a lower alkoxy group, a cyclo lower alkoxy group, a hydroxy group substituted by a heterocyclic ring containing N atom(s), or an amino group (each of which is optionally substituted), and R3 and a substituent in Y may be combined to form a lactone ring. The compound of the present invention has excellent selective PDE V inhibitory activity and therefore, is useful as a therapeutic or prophylactic drug for treating various diseases due to functional disorders on cGMP-signaling.
    公式(I)的环状化合物或其药理学上可接受的盐,其中X为═CH—或═N—,Y为—NH—、—NR4—、—S—、—O—、—CH═N—、—N═CH—、—N═N—、—CH═CH—等,R1为较低的烷氧基、氨基、含有N原子的杂环环或被含有N原子的杂环环取代的羟基(每个都可以选择性地取代),R2为较低的烷基氨基基,其可选择性地被芳基基团取代,较低的烷氧基,其可选择性地被芳基基团取代,被含有N原子的芳杂环取代的较低的烷氧基,R3为芳基、含有N原子的杂环环、较低的烷基、较低的烷氧基、环状较低烷氧基、被含有N原子的杂环环取代的羟基或氨基(每个都可以选择性地取代),并且R3和Y中的取代基可以结合形成内酯环。本发明化合物具有优异的选择性PDE V抑制活性,因此,可用作治疗或预防因cGMP信号传导功能障碍引起的各种疾病的药物。
  • CYCLIC COMPOUNDS
    申请人:TANABE SEIYAKU CO., LTD.
    公开号:EP1277741A1
    公开(公告)日:2003-01-22
    1. A cyclic compound of the formula (I) or a pharmacologically acceptable salt thereof,    wherein X is =CH-or=N-, Y is-NH-, -NR4-, -S-, - O-, -CH=N-, -N=CH-, -N=N-, -CH=CH-, etc., R1 is a lower alkoxy group, an amino group, a heterocyclic ring containing N atom(s), or a hydroxy group substituted by a heterocyclic ring containing N atom(s) (each of which is optionally substituted), R2 is a lower alkylamino group which is optionally substituted by an aryl group, a lower alkoxy group which is optionally substituted by an aryl group, a lower alkoxy group substituted by an aromatic heterocyclic ring containing N atom(s), R3 is an aryl group, a heterocyclic ring containing N atom(s), a lower alkyl group, a lower alkoxy group, a cyclo lower alkoxy group, a hydroxy group substituted by a heterocyclic ring containing N atom(s), or an amino group (each of which is optionally substituted), and R3 and a substituent in Y may be combined to form a lactone ring.    The compound of the present invention has excellent selective PDE V inhibitory activity and therefore, is useful as a therapeutic or prophylactic drug for treating various diseases due to functional disorders on cGMP-signaling.
    1.式(I)的环状化合物或其药理学上可接受的盐、 其中 X 是 =CH-or=N-, Y 是-NH-、-NR4-、-S-、-O-、-CH=N-、-N=CH-、-N=N-、-CH=CH-等、R1 是低级烷氧基、氨基、含 N 原子的杂环或被含 N 原子的杂环取代的羟基(其中每一个都可选择被取代), R2 是低级烷基氨基,可选择被芳基取代,低级烷氧基,可选择被芳基取代、R3 是芳基、含 N 原子的杂环、低级烷基、低级烷氧基、环低级烷氧基、被含 N 原子的杂环取代的羟基或氨基(其中每个基团都可选择被取代),R3 和 Y 中的一个取代基可结合形成一个内酯环。 本发明的化合物具有优异的选择性 PDE V 抑制活性,因此可用作治疗或预防药物,用于治疗因 cGMP 信号转导功能紊乱而引起的各种疾病。
查看更多